The rs1256031 of estrogen receptor beta gene is associated with type 2 diabetes
Por:
Herrera-Lopez E.E., Castelan-Martinez O.D., Suarez-Sanchez F., Gomez-Zamudio J.H., Peralta-Romero J.J., Cruz M., Valladares-Salgado A.
Publicada:
1 sep 2018
Ahead of Print:
1 ene 2018
Resumen:
Aim: To determine the association between the rs1256031 polymorphism and
risk of developing type 2 diabetes.
Materials and Methods: Cases and controls study. 597 individuals with
type 2 diabetes and 605 without it participated. Genotyping of the
rs1256031 polymorphism of the ER beta gene was performed by real-time
PCR using TaqMan assay. For the multivariate analysis, a multiple
logistic regression was performed that included the main confounding
variables.
Results and conclusion: A multiple logistic regression analysis was
performed, adjusting for age, WHR, BMI and gender. The dominant model
showed a protective effect compared to the TT genotype (OR = 0.596,
IC95% [0.458-0.776]). Discussion. The proportions of native American,
European and African ancestry were characterized and no difference was
found in the study groups. The protective effect obtained in the
dominant model could to be due a regulatory function in the
transcription or the processing of the primary transcript. Our result
are the first to report an association between the polymorphism
rs1256031 and the reduction of the risk of T2D in the Mexican
population. The rs1256031 polymorphism show reduced risk of developing
T2D and is potential markers for predicting T2D. (C) 2018 Diabetes
India. Published by Elsevier Ltd. All rights reserved.
Filiaciones:
Herrera-Lopez E.E.:
Unidad de Investigacion Medica en Bioquimica, Centro Medico Nacional Siglo XXI, Instituto Mexicano del Seguro Social, Mexico City, Mexico
Inst Mexicano Seguro Social, Ctr Med Nacl Siglo XXI, Unidad Invest Med Bioquim, Ave Cuauhtemoc 330, Mexico City 06720, DF, Mexico
Castelan-Martinez O.D.:
Facultad de Estudios Superiores Zaragoza, Universidad Nacional Autónoma de México, Mexico City, Mexico
Univ Nacl Autonoma Mexico, Fac Estudios Super Zaragoza, Mexico City, DF, Mexico
Suarez-Sanchez F.:
Unidad de Investigacion Medica en Bioquimica, Centro Medico Nacional Siglo XXI, Instituto Mexicano del Seguro Social, Mexico City, Mexico
Inst Mexicano Seguro Social, Ctr Med Nacl Siglo XXI, Unidad Invest Med Bioquim, Ave Cuauhtemoc 330, Mexico City 06720, DF, Mexico
Gomez-Zamudio J.H.:
Unidad de Investigacion Medica en Bioquimica, Centro Medico Nacional Siglo XXI, Instituto Mexicano del Seguro Social, Mexico City, Mexico
Inst Mexicano Seguro Social, Ctr Med Nacl Siglo XXI, Unidad Invest Med Bioquim, Ave Cuauhtemoc 330, Mexico City 06720, DF, Mexico
Peralta-Romero J.J.:
Unidad de Investigacion Medica en Bioquimica, Centro Medico Nacional Siglo XXI, Instituto Mexicano del Seguro Social, Mexico City, Mexico
Inst Mexicano Seguro Social, Ctr Med Nacl Siglo XXI, Unidad Invest Med Bioquim, Ave Cuauhtemoc 330, Mexico City 06720, DF, Mexico
Cruz M.:
Unidad de Investigacion Medica en Bioquimica, Centro Medico Nacional Siglo XXI, Instituto Mexicano del Seguro Social, Mexico City, Mexico
Inst Mexicano Seguro Social, Ctr Med Nacl Siglo XXI, Unidad Invest Med Bioquim, Ave Cuauhtemoc 330, Mexico City 06720, DF, Mexico
Valladares-Salgado A.:
Unidad de Investigacion Medica en Bioquimica, Centro Medico Nacional Siglo XXI, Instituto Mexicano del Seguro Social, Mexico City, Mexico
Inst Mexicano Seguro Social, Ctr Med Nacl Siglo XXI, Unidad Invest Med Bioquim, Ave Cuauhtemoc 330, Mexico City 06720, DF, Mexico
|